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Background: On the basis of pre-clinical evidence that high-dose plasmid-mediated vascular endothelial growth factor-165 (pVEGF) gene 
transfer induced angio-arteriogenesis and cardiomyogenesis with no side effects in pig and sheep models of myocardial ischemia, we conducted 
a Phase I, open-label, uncontrolled clinical trial of intramyocardial pVEGF gene transfer in patients with coronary artery disease not amenable for 
revascularization.
Methods: Ten no-option patients with stable chronic angina, myocardial ischemia and/or viability and ejection fraction (EF%) ≥ 30%, with negative 
screening for cancer (American Cancer Society) and proliferative retinopathy received 10 intramyocardial aliquots of pVEGF (total dose: 3.8 mg) with 
an injection catheter (MyoCath®, Bioheart Inc.).
Results: No serious adverse events related to pVEGF or the catheter were observed at 6 (out of 24) months follow up. The Table shows baseline 
vs. 6-months values for angina functional class (CCS-FC), Seattle Angina Questionnaire for quality of life (SAQ%), summed difference score (SDS) of 
myocardial perfusion (99mTc-MIBI SPECT) and EF% under dobutamine stress echo. Ten days after injection, plasma VEGF protein (ELISA) displayed a 
significant 3-fold increase vs. baseline.
Conclusion: pVEGF gene transfer at doses that duplicate those used so far is safe, improves symptoms, reduces myocardial ischemia and improves 
EF% at 6 months follow up. These results must be confirmed by randomized, pacebo-controlled trials.
Baseline versus 6-months results (efficacy)
CCS-FC (median - range) SAQ% (median - range) SDS (mean ± SEM) EF% (median - range)
Baseline 2.5 (2 - 3) 57.8 (35.3 - 70.8) 13.1 ± 1.9 43.5 (25 - 66)
6 months 1 (0 - 3) 83.3 (68.8 - 91.3) 9.5 ± 2.4 50 (30 - 65)
p (Wilcoxon) <0.01 <0.01 <0.04 <0.02
